Decitabine plus busulfan–cyclophosphamide versus busulfan–cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial

The Lancet Haematology · Elsevier

Аннотация

Publication date: November 2026 Source: The Lancet Haematology, Volume 13, Issue 11 Author(s): Zhongli Hu, Zhiping Fan, Min Dai, Hai He, Hua Jin, Zhiqiang Sun, Fen Huang, Na Xu, Qianwei Liu, Yiqing Li, Ying Dong, Ping Zhu, Can Liu, Yunxin Zeng, Jing Sun, Ruijuan Sun, Li Xuan, Qifa Liu

Читать у издателя →

Похожие статьи